Acute primary angle-closure
Conditions
Interventions
A:Subconjunctival 2.5 mg of dexamethasone disodium phosphate. Other drug treatment were the same with the control group
B:Topical pilocarpine 1% four times daily, topical beta-blocker (timolol 0.5%) twice daily and/or brinzolamide (Azopt
Alcon Laboratories, Elkridge, MD), and/or topical alpha-2 agonists (Alphagan
Allergan, Inc., Irvine, CA), oral acetazolamide 250 mg three times daily and intravenous mannitol 20% 250ml one time
Sponsors
Zhongshan Ophthalmic Center, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Subjects were diagnosed as APAC; 2.One eye was experiencing APAC for the first time; 3.Subjects were >40 years old.
Exclusion criteria
Exclusion criteria: 1.A secondary acute attack because of lens subluxation, uveitis, iris neovascularization, trauma, tumor, or any obvious cataract leading to an intumescent lens; 2.A history of previous ocular surgery; 3.A known inflammatory, autoimmune, or immunosuppressive disease; 4.A pre-existing ocular disease (retinal vein occlusion, retinal artery occlusion, diabetic retinopathy, age-related macular degeneration); 5.Diabetes patients; 6.Hypersensitivity reaction history of dexamethasone and its analogues; 7.Has topical used anti-inflammatory drugs, including: NASIDs, hormones; 8.Pregnant women, one-eyed, and other disabled people.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Inflammation-related cytokines of aqueous humor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anterior chamber cells;Anterior chamber flare;conjunctival erythema;Visual acuity;Corneal edema;Complication;Pupillary size and reaction; | — |
Countries
China
Contacts
Public ContactXiulan Zhang
Outcome results
None listed